Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction

Thrombosis and Haemostasis

Volumn 108, Issue 4, 2012, Pages 781-788

  Kurnik, Daniel ^a,b,d   Qasim, Husam ^a   Sominsky, Sophie ^b   Lubetsky, Aharon ^a,b   Markovits, Noa ^a   Li, Chun ^c   Michael Stein, C ^d   Halkin, Hillel ^a,b   Gak, Eva ^b   Loebstein, Ronen ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Dose prediction; Ethnicity; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

WARFARIN;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIMULATION; VKORC1 GENE;

AGED; ALGORITHMS; AMINO ACID SUBSTITUTION; ANTICOAGULANTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; ISRAEL; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; WARFARIN;

EID: 84867263459     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-03-0151     Document Type: Article

References (45)

1. Kurnik D, Loebstein R, Halkin H, et al. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics 2009; 10: 1955-1965.
2. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90: 625-629.
3. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764
4. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-331
5. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
6. Gong IY, Schwarz UI, Crown N, et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One 2011; 6: e27808.
7. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83: 460-470.
8. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-2570.
9. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55: 2804-2812.
10. Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011; 118: 3163-3171.
11. Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation 2011; 124: 2554-2559.
12. FDA approves updated warfarin sodium label. Available at http://www.fda.gov/Safety/MedWatch/SAfetyInformation/ucm201100.htm. Last accessed on January 31, 2012. 2010.
13. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-3834.
14. Botton MR, Bandinelli E, Rohde LE, et al. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 2011; 72: 442-450.
15. Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 2011; 12: 125-134.
16. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101-110.
17. D'Ambrosio RL, D'Andrea G, Cafolla A, et al. A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme. J Thromb Haemost 2007; 5: 191-193.
18. Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109: 2477-2480.
19. Watzka M, Geisen C, Bevans CG, et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost 2011; 9: 109-118.
20. Bodin L, Perdu J, Diry M, et al. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost 2008; 6: 1436-1439.
21. Vecsler M, Loebstein R, Almog S, et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95: 205-211.
22. Loebstein R, Vecsler M, Kurnik D, et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005; 77: 365-372.
23. Shaw PB, Donovan JL, Tran MT, et al. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis 2010; 30: 220-225.
24. IWPC algorithm. Available at http://www.pharmgkb.org/drug/PA451906 Last accessed on January 31. IWPC algorithm.
25. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-4112.
26. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012; 13: 407-418.
27. Scott SA, Edelmann L, Kornreich R, et al. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008; 82: 495-500.
28. Aklillu E, Leong C, Loebstein R, et al. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 2008; 111: 3903-3904.
29. Harrington DJ, Gorska R, Wheeler R, et al. Pharmacodynamic resistance to war-farin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 2008; 6: 1663-1670.
30. Shuen AY, Wong BY, Fu L, et al. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Clin Biochem 2012; 45: 397-401.
31. Pavani A, Naushad SM, Rupasree Y, et al. Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J 2012; 12: 306-311.
32. Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 2011; 12: 953-963.
33. Harrington DJ, Siddiq S, Allford SL, et al. More on: endoplasmic reticulum loop VKORC1 substitutions cause warfarin resistance but do not diminish gammacarboxylation of the vitamin K-dependent coagulation factors. J Thromb Haemost 2011; 9: 1093-1095.
34. Suarez-Kurtz G. Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol 2011; 72: 451-453.
35. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-1027.
36. Zhang JE, Jorgensen AL, Alfirevic A, et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 2009; 19: 781-789.
37. Perini JA, Struchiner CJ, Silva-Assuncao E, et al. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 2010; 87: 417-420.
38. Bejarano-Achache I, Levy L, Mlynarsky L, et al. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. Clin Ther 2012; 34: 811-823.
39. King CR, Deych E, Milligan P, et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 2010; 104: 750-754.
40. Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112: 572-577.
41. Braam L, McKeown N, Jacques P, et al. Dietary phylloquinone intake as a potential marker for a heart-healthy dietary pattern in the Framingham Offspring cohort. J Am Diet Assoc 2004; 104: 1410-1414.
42. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 2001; 70: 159-164.
43. Lurie Y, Loebstein R, Kurnik D, et al. Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol 2010; 70: 164-170.
44. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-1105.
45. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.